Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948] (International Journal of Antimicrobial Agents (2020) 55(6), (S0924857920300984), (10.1016/j.ijantimicag.2020.105948));Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

International Journal of Antimicrobial Agents

Volumn 55, Issue 6, 2020, Pages

  Wang, Lisheng ^a   Wang, Yiru ^a   Ye, Dawei ^a   Liu, Qingquan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Coronavirus; COVID 19; Pneumonia; Respiratory infection; SARS CoV 2

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIVIRUS AGENT; ARBIDOL; ASCORBIC ACID; ATRACTYLODES MACROCEPHALA EXTRACT; BAICALIN; CHINESE DRUG; CHLOROGENIC ACID; CHLOROQUINE; FANGFENG; FORSYTHIN; GLYCYRRHIZA GLABRA ROOT; IMMUNOGLOBULIN; LIANHUAQINGWEN; LOPINAVIR PLUS RITONAVIR; NUCLEOSIDE DERIVATIVE; REMDESIVIR; SHUANGHUANGLIAN; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; ASTRAGALUS (PLANT); BLOOD PURIFICATION THERAPY; CHINESE MEDICINE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENT PLASMA THERAPY; CORONAVIRUS DISEASE 2019; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; EMERGENCY HEALTH SERVICE; EVIDENCE BASED PRACTICE; GENE STRUCTURE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION PREVENTION; LIFESTYLE; LONICERA; NONHUMAN; PANDEMIC; PATHOGENESIS; PERSONAL HYGIENE; PLASMAPHERESIS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS TRANSMISSION; VITAMIN SUPPLEMENTATION; BETACORONAVIRUS; CLASSIFICATION; CORONAVIRUS INFECTION; GENETICS; HOST RANGE; PASSIVE IMMUNIZATION; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; VIRUS GENOME; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; GENOME, VIRAL; HOST SPECIFICITY; HUMANS; IMMUNIZATION, PASSIVE; PANDEMICS; PNEUMONIA, VIRAL; PREVALENCE;

EID: 85082811635     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2020.106137     Document Type: Erratum

References (73)

1. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
2. Liu, Y., Gayle, A.A., Wilder-Smith, A., Rocklov, J., The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med, 27(2), 2020, taaa021, 10.1093/jtm/taaa021.
3. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:10223 (2020), 507–513.
4. World Health Organization. Coronavirus disease 2019 (COVID-19). 2020, WHO, Geneva Situation Report 40.
5. Chan, J.F., To, K.K., Tse, H., Jin, D.Y., Yuen, K.Y., Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 21 (2013), 544–555.
6. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:8 (2020), 727–733.
7. Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27:3 (2020), 325–328.
8. Hoffmann, M., Kleine-Weber, H., Krüger, N., Müller, M., Drosten, C., Pöhlmann, S., The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv, 2020 2020.01.31.929042.
9. Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (New York, NY) 367:6483 (2020), 1260–1263.
10. Remais, J., Modelling environmentally-mediated infectious diseases of humans: transmission dynamics of schistosomiasis in China. Adv Exp Med Biol 673 (2010), 79–98.
11. Wu, J.T., Leung, K., Leung, G.M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 395:10225 (2020), 689–697.
12. Majumder, M.A.M., Kenneth, D., Early transmissibility assessment of a novel coronavirus in Wuhan, China. SSRN, 2020, 10.2139/ssrn.3524675.
13. Lipsitch, M., Cohen, T., Cooper, B., Robins, J.M., Ma, S., James, L., et al. Transmission dynamics and control of severe acute respiratory syndrome. Science (New York, NY) 300 (2003), 1966–1970.
14. Majumder, M.S., Rivers, C., Lofgren, E., Fisman, D., Estimation of MERS-coronavirus reproductive number and case fatality rate for the Spring 2014 Saudi Arabia outbreak: insights from publicly available data. PLoS Curr, 6, 2014, 10.1371/currents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c.
15. Guan, W-J, Ni, Z-Y, Hu, Y, Liang, W-H, Ou, C-Q, He, J-X, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med, 2020, 10.1056/NEJMoa2002032.
16. Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, 10.1001/jama.2020.2648.
17. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395 (2020), 507–513.
18. Barreto, M.L., Teixeira, M.G., Carmo, E.H., Infectious diseases epidemiology. J Epidemiol Community Health 60 (2006), 192–195.
19. Ji, W., Wang, W., Zhao, X., Zai, J., Li, X., Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol, 92, 2020, 10.1002/jmv.25682.
20. Zhang, C., Zheng, W., Huang, X., Bell, E.W., Zhou, X., Zhang Y.Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1. J Proteome Res 19:4 (2020), 1351–1360.
21. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:7798 (2020), 270–273.
22. Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63:3 (2020), 457–460.
23. Wang, J., Zhao, S., Liu, M., Zhao, Z., Xu, Y., Wang, P., et al. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. medRxiv, 2020, 2020 2020.02.05.20020545.
24. Xiao, F., Tang, M., Zheng, X., Li, C., He, J., Hong, Z., et al. Evidence for gastrointestinal infection of SARS-CoV-2. medRxiv, 2020 2020.02.17.20023721.
25. Xia, J., Tong, J., Liu, M., Shen, Y., Guo, D., Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol, 2020, 10.1002/jmv.25725.
26. Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 395:10226 (2020), 809–815.
27. Wang, W., Tang, J., Wei, F., Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 92 (2020), 441–447.
28. Lessler, J., Reich, N.G., Brookmeyer, R., Perl, T.M., Nelson, K.E., Cummings, D.A., Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis 9 (2009), 291–300.
29. Cho, S.Y., Kang, J.M., Ha, Y.E., Park, G.E., Lee, J.Y., Ko, J.H., et al. MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study. Lancet 388 (2016), 994–1001.
30. Chan, P.K., Tang, J.W., Hui, D.S., SARS: clinical presentation, transmission, pathogenesis and treatment options. Clin Sci 110 (2006), 193–204.
31. Yang, Y., Lu, Q., Liu, M., Wang, Y., Zhang, A., Jalali, N., et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv, 2020, 2020 2020.02.10.20021675.
32. Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C., et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan: China: a retrospective case series study. medRxiv, 2020 2020.02.22.20026500.
33. Ai, T., Yang, Z., Hou, H., Zhan, C., Chen, C., Lv, W., et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology, 2020, 200642, 10.1148/radiol.2020200642.
34. Li, Z., Wu, M., Guo, J., Yao, J., Liao, X., Song, S., et al. Caution on kidney dysfunctions of 2019-nCoV patients. medRxiv, 2020, 2020 2020.02.08.20021212.
35. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020.
36. Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:4 (2020), 420–422.
37. Xiao F., Tang M., Zheng X., Li C., He J., Hong Z., et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology doi: 10.1053/j.gastro.2020.02.055.
38. Wong, K.T., Antonio, G.E., Hui, D.S., Lee, N., Yuen, E.H., Wu, A., et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 228 (2003), 401–406.
39. Shi, H., Han, X., Jiang, N., Cao, Y., Alwalid, O., Gu, J., et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 20:4 (2020), 425–434.
40. Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv, 2020 2020.02.10.20021832.
41. China National health commission. The novel coronavirus pneumonia diagnosis and treatment plan (5th trial version). 2020.
42. China National health commission. The novel coronavirus pneumonia diagnosis and treatment plan (6th trial version). 2020.
43. Zhang F., OmarAbudayyeh O., Gootenberg J.S. https://www.broadinstitute.org/files/publications/special/COVID-19%20detection%20(updated).pdf.
44. Di, L., Fu, Y., Sun, Y., Li, J., Liu, L., Yao, J., et al. RNA sequencing by direct tagmentation of RNA/DNA hybrids. Proc Natl Acad Sci USA 117 (2020), 2886–2893.
45. Holshue, M.L., DeBolt, C., Lindquist, S., Lofy, K.H., Wiesman, J., Bruce, H., et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 382:10 (2020), 929–936.
46. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:3 (2020), 269–271.
47. Gao, J., Tian, Z., Yang, X., Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:1 (2020), 72–73.
48. Boriskin, Y.S., Leneva, I.A., Pecheur, E.I., Polyak, S.J., Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15 (2008), 997–1005.
49. Khamitov, R.A., Loginova, S., Shchukina, V.N., Borisevich, S.V., Maksimov, V.A., Shuster, A.M., [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Vopr Virusol 53 (2008), 9–13.
50. Lu, H., Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 14:1 (2020), 69–71.
51. Li, W., [The curative effect observation of shuanghuanglian and penicillin on acute tonsillitis]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 16 (2002), 475–476.
52. Lu, H.T., Yang, J.C., Yuan, Z.C., Sheng, W.H., Yan, W.H., [Effect of combined treatment of Shuanghuanglian and recombinant interferon alpha 2a on coxsackievirus B3 replication in vitro]. Zhongguo Zhong Yao Za Zhi 25 (2000), 682–684.
53. Chen, X., Howard, O.M., Yang, X., Wang, L., Oppenheim, J.J., Krakauer, T., Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function. Life Sci 70 (2002), 2897–2913.
54. Ding, Y., Zeng, L., Li, R., Chen, Q., Zhou, B., Chen, Q., et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med, 17, 2017, 130.
55. Loutfy, M.R., Blatt, L.M., Siminovitch, K.A., Ward, S., Wolff, B., Lho, H., et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290 (2003), 3222–3228.
56. Mustafa, S., Balkhy, H., Gabere, M.N., Current treatment options and the role of peptides as potential therapeutic components for Middle East respiratory syndrome (MERS): a review. J Infect Public Health 11 (2018), 9–17.
57. Gilardin, L., Bayry, J., Kaveri, S.V., Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ 187 (2015), 257–264.
58. Kumar, V., Jung, Y.S., Liang, P.H., Anti-SARS coronavirus agents: a patent review (2008– present). Expert Opin Ther Pat 23 (2013), 1337–1348.
59. Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., Cleary, P., Khaw, F.M., Lim, W.S., et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211 (2015), 80–90.
60. Soo, Y.O., Cheng, Y., Wong, R., Hui, D.S., Lee, C.K., Tsang, K.K., et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 10 (2004), 676–678.
61. Hung, I.F., To, K.K., Lee, C.K., Lee, K.L., Chan, K., Yan, W.W., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52 (2011), 447–456.
62. Baron, S., (eds.) Medical microbiology, 4th edition, 1996, University of Texas Medical Branch, Galveston, TX.
63. Cheng, Y., Wong, R., Soo, Y.O., Wong, W.S., Lee, C.K., Ng, M.H., et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24 (2005), 44–46.
64. Zarbock, A., Kellum, J.A., Schmidt, C., Van Aken, H., Wempe, C., Pavenstadt, H., et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA 315 (2016), 2190–2199.
65. Lim, C.C., Tan, C.S., Kaushik, M., Tan, H.K., Initiating acute dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: a prospective cohort study. Nephrology 20 (2015), 148–154.
66. Zhang, L., Liu, Y., Potential interventions for novel coronavirus in China: a systematic review. J Med Virol 92:5 (2020), 479–490.
67. Lau, J.T., Leung, P.C., Wong, E.L., Fong, C., Cheng, K.F., Zhang, S.C., et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. J Altern Complement Med 11 (2005), 49–55.
68. Luo, H., Tang, Q.L., Shang, Y.X., Liang, S.B., Yang, M., Robinson, N., et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 26:4 (2020), 243–250.
69. Hemila, H., Vitamin C intake and susceptibility to pneumonia. Pediatr Infect Dis J 16 (1997), 836–837.
70. Nonnecke, B.J., McGill, J.L., Ridpath, J.F., Sacco, R.E., Lippolis, J.D., Reinhardt, T.A., Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves. J Dairy Sci 97 (2014), 5566–5579.
71. Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21:3 (2020), 335–337.
72. High, K.P., Nutritional strategies to boost immunity and prevent infection in elderly individuals. Clin Infect Dis 33 (2001), 1892–1900.
73. Simpson, R.J., Kunz, H., Agha, N., Graff, R., Exercise and the regulation of immune functions. Prog Mol Biol Transl Sci 135 (2015), 355–380, 10.1016/bs.pmbts.2015.08.001.